Gilead a Core Biotech Holding – Analyst Blog
Source: http://www.zacks.com/stock/news/16379/Gilead+a+Core+Biotech+Holding+-+Analyst+BlogPosted on Friday, December 12th, 2008 | In Stocks to Watch
Gilead Sciences, Inc. (GILD) is a biotechnology company that develops and markets drugs for infectious diseases, including viral, fungal and bacterial infections. The company also has specialized focus on developing drugs for patients suffering from HIV/AIDS.
We remain optimistic about growth of HIV/AIDS franchise drugs Truvada and the recently approved Atripla. Earnings over the past few quarters have been above expectations, specifically on strong sales of the HIV franchise products.
We continue to be positive on the name and would recommend opportunistic buying at this level. We view the name as a core biotech to own. Our target is $52.
Read the full analyst report on GILD
“GILD” Free Stock Analysis: Buy? Sell? Hold?
Zacks Investment Research
Last 5 posts by Zacks Market Commentaries
- CNP & FPL Ink Pipeline Deal - Analyst Blog - November 20th, 2009
- Buffett Borrows for Rail Acquisition - Analyst Blog - November 20th, 2009
- Stone Energy Outdoes Estimates - Analyst Blog - November 20th, 2009
- Smucker's Beats, Raises Guidance - Analyst Blog - November 20th, 2009
- GameStop Meets Expectations - Analyst Blog - November 20th, 2009
bacterial infections, Biotechnology, Blog, franchise products, Gilead Sciences Inc, HIV/AIDS, Infectious Diseases, Stocks to Watch, Truvada, USD, Zacks Market Commentaries
 About Zacks Market Commentaries (http://www.zacks.com/)
Zacks Market Commentaries |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.